Fluoxetine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fluoxetine: From Major Depressive Disorder to Histrionic Personality Disorder
One-Sentence Summary
Fluoxetine (DrugBank DB00472) is a selective serotonin reuptake inhibitor (SSRI) whose established use, as reflected throughout the collected literature, is major depressive disorder and related mood/anxiety-spectrum conditions. The TxGNN model predicts it may be effective for Histrionic Personality Disorder, but currently only 3 indirectly related publications and no registered clinical trials support this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major depressive disorder (SSRI antidepressant class; no formal regulatory license record available in this evidence pack) |
| Predicted New Indication | Histrionic Personality Disorder |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| US Market Status | 未上市 (Not Marketed — no license record captured in this dataset) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on the surrounding literature context (drawn from trials and reviews for other predicted indications in this dataset), fluoxetine is an SSRI-class antidepressant that enhances serotonergic neurotransmission through selective inhibition of neuronal serotonin reuptake, with well-established efficacy in major depressive disorder, panic disorder, and social anxiety.
Histrionic personality disorder is characterized by excessive emotionality, attention-seeking behavior, and affective instability — domains that are theoretically linked to serotonergic regulation of mood and impulse control. This provides a plausible, but indirect, biological rationale for the TxGNN prediction.
However, none of the three retrieved publications directly studies fluoxetine treatment of histrionic personality disorder. They cover a body dysmorphic disorder case report, a review of psychiatric manifestations of lupus/Sjögren’s syndrome, and an MMPI-2 rating-scale study in depressed patients — all only tangentially related. As noted in the evidence rationale, the mechanistic link here remains speculative rather than confirmed.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11865567 | 2001 | Review | L’Encephale | Reviews psychiatric manifestations of systemic lupus erythematosus and Sjögren’s syndrome, including a case with predominant psychiatric agitation; not specific to histrionic personality disorder or fluoxetine treatment |
| 22075735 | 2011 | Cohort (rating-scale study) | Psychiatria Danubina | Examines MMPI-2 neurotic triad subscales (including hysteria) and depression levels after pharmacological treatment in depressive disorder patients |
| 28791577 | 2018 | Case report | Neuropsychiatrie | “Barbie Doll Syndrome” case report of body dysmorphic disorder in a patient admitted for an eating disorder; no direct treatment data for histrionic personality disorder |
US Market Information
This drug currently has no marketing authorization records available in this evidence pack (US market status: 未上市, 0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information. (Note: TFDA label warnings/contraindications and DDI data are flagged as a Blocking data gap in this evidence pack — required before any safety review can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: There are no clinical trials and only three low-tier, indirectly related publications for this indication; the mechanistic link to histrionic personality disorder is speculative rather than evidence-based, and a Blocking data gap exists for core safety data (TFDA warnings/contraindications).
To proceed, the following is needed:
- TFDA/US label warnings, contraindications, and DDI data (currently Blocking gap)
- Detailed mechanism of action (MOA) data (currently High-severity gap)
- Confirmed original indication and regulatory license history for fluoxetine
- Dedicated clinical or case-series evidence evaluating fluoxetine specifically in histrionic personality disorder
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.